

ictmc.org @ictmc2024

ictmc@in-conference.org.uk

# Registration now open!

**Abstract Submission Opens** 8 January 2024

Abstract Submission Deadline 30 April 2024

> **Notification to Authors** 1 July 2024

**Early Registration Deadline** 23 August 2024

## **Abstract Submission Themes**

## DESIGN

- Adaptive designs Cluster RCT
- Complex interventions
- Diagnostic trials
- Health economics
- Innovative designs Interventions: selection
- Outcome measures: core outcome sets
- Outcome measures: patient-reported outcome measures
- Outcome measures: selection and derivation
- Pilot and feasibility studies
- Stratified medicine
- Studies within a trial (SWATs) Systematic reviews, meta-analysis and
- evidence synthesis

## CONDUCT

- Data management
- Equality, Diversity and Inclusion in Clinical trials
- Health economics
- Healthcare systems data / EHR / RCHD
- Information systems and technology Infrastructure, Collaboration & Global
- Health
- Recruitment and consent Retention and follow-up
- Safety and toxicity
- Trial management
- Trial monitoring, data quality & QC Studies within a trial (SWATs)
- Regulatory Issues/Engaging with regulators

### ANALYSIS

- Estimands
- Health economics
- Healthcare systems data / EHR / RCHD
- Machine learning/AI in clinical trials
- Missing data
- New statistical methods Studies within a trial (SWATs)
- Systematic reviews, meta-analysis and
- evidence synthesis Borrowing of information

## NEW & ONGOING

## CHALLENGES

- · Open Research, Data Sharing and Data
- Re-use Greener trials
- Reproducibility and research waste
- Synthetic data
- Unattended challenges
- Team Science
- De-centralised Trials
- Trials in small populations Research ethics/bioethics

### COMMUNICATION & DISSEMINATION

- Communication within trials Dissemination of Trial Evidence
- Measuring impact and changing policy

## PARTICIPANTS, PATIENTS &

- Research into Patient and Public Involvement (PPI)
- · Co-producing trials and methodology

#### CASE STUDIES

- Lessons from recent experience
- Lessons from trials in a disease area/population
- Lessons from trials in a region